Par-enteral drug delivery systems are the preparations that are given other than oral route. (Para-outside, enteric–intestine). ... The Par-enteral administration route is the most common and efficient for delivery of active drug substances with poor bio-availability and the drugs with a narrow therapeutic index.
2. CONTENTS
Introduction
Objective
Additives used in formulation
Routes of administration
Approaches for formulation
Type of formulation
Classification
Approaches for formulations of Implants
Infusion Devices
References
6/15/2020
5. Advantages over conventional drug
delivery system
Improved patient convenience and compliance.
Reduction in fluctuation in steady-state levels.
Increased safety margin of high potency drugs.
Maximum utilization of drug.
Reduction in health care costs through improved
therapy, shorter treatment period, less frequency of
dosing
6/15/2020
6. Disadvantages of controlled release
dosage forms
Decreased systemic availability
Poor in vitro-in vivo correlation
Possibility of dose dumping.
Retrieval of drug is difficult in case of toxicity,
poisoning or hypersensitivity reactions.
Reduced potential for dosage adjustments.
Higher cost of formulations.
6/15/2020
8. CHARACTERISTICS
Free from living microbes
Free from microbial products such as pyrogens
Should match the osmotic nature of the blood
Free from chemical contaminants
Matching specefic gravity
6/15/2020
9. ADDITIVES USED DURING FORMULATION
OF PARENTRALS
Vehicles
Stabilizers
Buffering agents
Tonicity factors
Solubilizers
Wetting, suspending, emulsifying agents
Antimicrobial compounds
6/15/2020
11. 116/15/2020
PARAMETERS MANIPULATED IN THE
DESIGN OF PARENTRAL CONTROLLED
FORMS
Route of administration
Vehicles
Vaso-constriction
Particle size
Chemical modification of drug
12. Approaches
Use of viscous, water-miscible vehicles, such as
an aqueous solution of gelatin or
polyvinylpyrrolidone.
Utilization of water-immiscible vehicles, such as
vegetable oils, plus water-repelling agent, such
as aluminum monostearate.
Formation of thixotropic suspensions.
6/15/2020
13. Preparation of water-insoluble drug derivatives,
such as salts, complexes, and esters.
Dispersion in polymeric microspheres or
microcapsules, such as lactide-glycolide
homopolymers or copolymers
Co-administration of vasoconstrictors.
6/15/2020
15. Dissolution type depot
formulations
Drug absorption is controlled by slow dissolution of
drug particles.
Rate of dissolution is given by ;
where,
Sa – Surface area of drug particles
Ds – Diffusion coefficient of drug
Cs – Saturation solubility of drug
hd – Thickness of hydrodynamic diffusion
6/15/2020
( Q
t )d
=
SaDsCs
hd
16. Drawbacks
Release of drug molecules is not of zero order
kinetics as expected from the theoretical model.
Surface area Sa of drug particles diminishes with
time.
The saturation solubility Cs of the drug at the
injection site cannot be easily maintained.
6/15/2020
17. Approaches
Formation of salts or Complexes with Low solubility.
E.g., Aqueous suspensions of benzathine penicillin G.
Suspension of macro crystals.
E.g., aqueous suspension of testosterone isobutyrate for
I.M. administration.
Exception
Penicillin G procaine suspension in gelled peanut oil for
I.M. injection.
6/15/2020
18. Adsorption-type Depot
Preparation
Formed by binding of drug molecules to adsorbents.
Only unbound, free species of drug is available for
absorption.
Equilibrium conc. of free, unbound drug species (C)f is
determined by the Langmuir relationship.
E.g., - Vaccine preparations
6/15/2020
1
a(C)b.m
(C)f
(C)b
= +
(C)f
(C)b,m
19. Encapsulation-type Depot
Preparations
Prepared by encapsulating drug solids within a
permeation barrier or dispersing drug particles in a
diffusion matrix.
Membrane – biodegradable or bioabsorbable
macromolecules
Gelatin, Dextran, polylactate, lactide-glycolide copolymers,
phospholipids, and long chain fatty acids and glycerides.
6/15/2020
20. Encapsulation-type Depot
Preparations
E.g., Naltrexone pamoate-releasing biodegradable
microcapsules.
Release of drug molecules is controlled by
Rate of permeation across the permeation barrier
The rate of biodegradation of the barrier macromolecules.
6/15/2020
21. Esterification-type Depot
Preparation
Esterifying a drug to form a bioconvertible prodrug-type ester.
Forms a reservoir at the site of injection.
Rate of absorption is controlled by
Interfacial partitioning of drug esters from reservoir
to tissue fluid.
Rate of bioconversion of drug esters to regenerate
active drug molecules.
E.g., Fluphenazine enanthate, nandrolone decanoate, and
testosterone 17B-cyprionate in oleaginous solution.
6/15/2020
23. Solutions
Aqueous solutions
High viscosity solutions
For comp. with mol. wt. more than 750
For water sol. drugs
Gelling agents or viscosity enhancers are used
Complex formulations
Drug forms dissociable complex with macromolecule
Fixed amount of drug gets complexed
Given by I.M. route
6/15/2020
24. Solutions
Oil solutions
Drug release is controlled by controlling
partitioning of drug out of oil into surrounding into
aqueous medium
For I.M. administration only
No. of oils are limited
6/15/2020
25. Suspensions
Aqueous suspensions
Given by I.M. or S.C. routes
Conc. of solids should be 0.5 to 5 %
Particle size should be < 10 μm
6/15/2020
26. Suspensions
Drug is continuosly dissolving to replenish the
lost.
For oil soluble drugs
Only crystalline and stable polymorphic drugs are
given by this form
Viscosity builders can be used.
E.g., Crystalline zinc insulin
6/15/2020
27. Suspensions
Oil suspensions
Given by I.M. route.
Process of drug availability consists of dissolution of
drug particles followed by partitioning of drug from
oil solution to aqueous medium.
More prolong dug action as compared to oil solution
and aqueous suspension.
E.g., Penicillin G procaine in vegetable oil
6/15/2020
28. Emulsions
Can be given by I.M., S.C., or I.V. routes
O/w systems are not used due to large interfacial
area and rapid partitioning.
W/o emulsions are used for water soluble drugs.
Multiple emulsions are used generally such as w/o/w
and o/w/o since an additional reservoir is presented
to the drug for partitioning which can effectively
retard its release rate.
6/15/2020
29. Emulsions
Release of water soluble drugs can be retarded by
presenting it as oil suspension and vice versa.
6/15/2020
Aqueous phase
Oil phase
Water soluble drug
e.g., 5-Fluorouracil
Oil soluble drug
e.g., lipidol
30. Microsphere
Each microsphere is basically a matrix of
drug dispersed in a polymer from which
release occurs by first order process.
Polymers used are biocompatible and
biodegradable.
Polylactic acid, polylactide coglycolide etc.
Drug release is controlled by dissolution
degradation of matrix.
Small matrices release drug at a faster rate.
6/15/2020
31. Microsphere
For controlled release of peptide/protein drugs such
as LHRH which have short half-lives.
Magnetic microspheres are developed for
promoting drug targeting which are infused into an
artery.
Magnet is placed over the area to localize it in that
region.
6/15/2020
32. Microcapsules
Drug is centrally located within the polymeric shell.
Release is controlled by dissolution, diffusion or
both.
For potent drugs such as steroids, peptides and
antineoplastics.
6/15/2020
33. Nanoparticles and Niosomes
Nanoparticles are called as nanospheres or
nanocapsules depending upon the position of drugs
Polymer used are biodegradable ones.
Polyacrylic acid, polyglycolic acid
For selective targeting therapy.
Nanosomes are closed vesicles formed in aqueous
media from nonionic surfactants with or without the
presence of lipids.
6/15/2020
34. Liposomes
Spherule/vesicle of lipid bilayers enclosing an
aqueous compartment.
Lipid most commonly used are phospholipids,
sphingolipids, glycolipids and sterols.
6/15/2020
liposomes
MLV OLV ULV
GUVMUV LUV
35. Liposomes
Water soluble drugs are trapped in aqueous
compartment.
Lipophilic ones are incorporated in the lipid phase of
liposomes.
Can be given by I.M., S.C., for controlled rate
release.
Can be given by I.V. for targeted delivery.
6/15/2020
37. Resealed Erythrocytes
Biodegradable, biocompatible, nonimmunogenic.
Can circulate intravascularly for days and allow large
amounts of drug to be carried.
Drug loading in erythrocytes is easy.
Damaged erythrocytes are removed by liver and
spleen.
6/15/2020
39. Advantages and Disadvantages
Advantages
More effective and more prolonged action
Small dose is sufficient
Disadvantages
Microsurgery is required
6/15/2020
40. Approaches to implantable drug delivery
CDD by diffusion Activation process Feedback regulated
Osmotic pressure
Vapour pressure
Magnetically activated
Phonophoresis
Hydration activated
Hydrolysis activated
Bioerosion
Bioresponsive
Polymer
membrane
Matrix
diffusion
Microreservoir
6/15/2020
41. Polymer membrane permeation
controlled DDS
Reservoir is solid drug or
dispersion of solid drug in liquid or
solid medium.
Drug enclosed in reservoir and
reservoir is enclosed in rate
limiting polymeric membrane.
6/15/2020
Polymeric
membrane
nonporous
microporous
semipermeable
42. Polymer membrane permeation
controlled DDS
Encapsulation of drug in reservoir can be done by
encapsulation, microencapsulation, extrusion,
molding or any other technique.
E.g., Norplant Subdermal Implant.
6/15/2020
43. Polymer Matrix diffusion controlled DDS
Drug is homogeneously
dispersed throughout
polymer matrix.
Polymers used are :
Lipophilic polymers
Hydrophilipic polymers
Porous
Decreasing release with
time
E.g., Compudose implant
6/15/2020
44. Membrane-Matrix Hybrid type Drug
Delivery Device
Hybrid of first two
Minimizes the risk of dose dumping
Drug reservoir is homogeneous dispersion of
drug solids throughout a polymer matrix, and
is further encapsulated by polymeric
membrane
E.g., Norplant II Subdermal Implant
6/15/2020
45. Microreservoir Partition Drug
Delivery Device
Drug reservoir is a suspension
of drug crystals in an aqueous
solution of polymer.
Device is further coated with
layer of biocompatible
polymer.
Polymer used for matrix :
water soluble polymers
Polymer used for coating :
semipermeable polymer
6/15/2020
47. Controlled drug delivery by activation
process
Osmotic pressure activated
Vapor pressure activated
Magnetically activated
6/15/2020
48. Osmotic pressure activated
Osmotic pressure
is used as energy
source
Drug reservoir is
either a solution
or semisolid
formulation
Cellulosic outer
membrane
Polyester internal
membrane
6/15/2020
49. Vapor pressure activated
Vapor pressure is used as the power source.
Drug reservoir is a solution formulation.
Fluid which vaporizes at body temperature is used such
as fluorocarbon.
E.g., Infusaid Pump for Heparin.
6/15/2020
51. Magnetically activated
Electromagnet is used as power source.
Drug can be triggered to release at varying rates
depending upon the magnitude and the duration of
electromagnetic energy applied.
A tiny donut shaped magnet at the centre of medicated
polymer matrix that contains a homogeneous
dispersion of drug
It has low polymer permeability.
6/15/2020
52. Magnetically activated
External surface is coated with pure polymer, such
as ethylene vinyl acetate copolymer or silicone
copolymer.
The drug is activated to release at much higher rate
by applying the external magnetic field.
6/15/2020
55. Hydration activated
Releases drug upon activation by hydration
of device by tissue fluid at the implantation
site.
Hydrohilic polymer is used for formulation
which becomes swollen upon hydration.
Drug gets released by diffusing through the
water saturated pore channels in the swollen
polymer matrix.
E.g., Norgestomet releasing Hydron Implant
6/15/2020
56. Hydrolysis activated
Release drug upon hydrolysis of polymer base by
tissue fluid at implantation site.
Polymer used is bioerodible or biodegradable
polymer.
Pellet or bead shaped implant.
Rate of drug release is determined by rate of
biodegradation, polymer composition and mol. Wt.,
drug leading and drug polymer interactions.
Erosion rate is controlled by using a buffering agent.
6/15/2020
58. Infusion devices
The implantable infusion pump (IIP) is a drug
delivery system that provides continuous infusion of
an agent at a constant and precise rate.
The purpose of an IIP is to deliver therapeutic levels
of a drug directly to a target organ or compartment.
It is frequently used to deliver chemotherapy directly
to the hepatic artery or superior vena cava.
6/15/2020
60. RECENT DEVELOPMENTS
LIPOSOMES
Passive tumour targeting
Vaccine adjuvants
Passive targeting to lung endothelium in gene delivery
Targeting to regional lymph nodes
Targeting to cell surface ligands in various organs/areas of
pathology
Sustained release depot at point of injection
6/15/2020
61. Niosomes
Passive tumour targeting
Vaccine adjuvants
Sustained release depot at point of injection
Nanoparticles
Passive tumour targeting
Vaccine adjuvants
6/15/2020
62. Microparticles:
Sustained release depot at point of injection.
Vaccine adjuvants
Implant system:
Localised depot systems for the treatment of infections and
cancers. Sustained drug release systemic therapies
6/15/2020
RECENT DEVELOPMENTS
63. ADEPT
Active tumour targeting
It is an Antibody Directed Enzyme Prodrug Therapy
An antibody enzyme conjugate is administered
intravenously , localises in tumour tissue and
subsequently activates an administered prodrug
predominantly within such tumours
6/15/2020
64. EMULSION
Lipophilic drug administration vehicles
Targeting to cell surface antigens
These are the dispersions of one liquid inside the other
liquid
Droplet size of 100-200nm which results in high drug
liver uptake on I.V injection
6/15/2020
65. CYCLODEXTRIN
Lipophilic drug solubilisation for parenteral use
These compounds form inclusion complexes with
hydrophobic guest molecule
Modfied cyclodextrins such as hydroxypropyl b-
cyclodextrin and sulphobutyl b-cyclodextrins are
regardedas safe for parentral use
6/15/2020
66. POLYMER DRUG CONJUGATES
Passive tumour targeting
These include soluble polymeric prodrugs of
daunorudicin, doxorubicin, cisplatin and 5- flurouracil
These PDC accumulate selectively within tumour tissues
6/15/2020
68. 686/15/2020
“Parenteral Drug Delivery and Delivery Systems”, in
“Controlled Drug Delivery System” by Y.W.Chein;
Marcel Decker Publications Vol. 50 pg – 381 -513.
“Parenteral Drug Delivery”, in “Targeted and Controlled
Drug Delivery” by Vyas and Khar pg – 30-33.
“Parenteral Products”, in “Controlled Drug Delivery” by
Robinson and Lee; Marcel Decker Publications, Vol. 29
pg – 433 – 450.
References
69. “Parenterals” in “Sterile Dosage Forms and Delivery
Systems” by Ansel, pg 444-451, 488-489.
“Parenteral Drug Delivery Systems” in “Encyclopedia of
Controlled Drug Delivery System” pg 752-753.
“Controlled Release Medication” in “Biopharmaceutics
and Pharmacokinetics A Treatise” by D.M.Brahmankar,
Sunil B. Jaiswal; pg 357-365.
http://www.pharmainfo.net
www.pharmj.com/.../education/parenteral2.html
6/15/2020